Other · developed by Mereo BioPharma
BCT197 is a drug studied in patients with chronic obstructive pulmonary disease and acute kidney injury.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01336959 | Phase 2 | Acute Kidney Injury | Terminated | MREO |
| NCT01332097 | Phase 2 | Chronic Obstructive Pulmonary Disease | Completed | MREO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Kidney InjuryChronic Obstructive Pulmonary Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the MREO page.
See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MREO catalysts and pipeline →